<DOC>
	<DOC>NCT02404922</DOC>
	<brief_summary>This study will assess in healthy male and female subjects the safety, tolerability and pharmacokinetics (PK) profiles of Immediate Release CTP-730 at steady state following 7 days of dosing. Three doses of Immediate Release (IR) CTP-730 capsules will be studied.</brief_summary>
	<brief_title>Multiple Ascending Dose Study in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy adult males and females between 18 and 50 years of age. Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2 Medical, psychiatric illness or history of depression that could, in the investigator's opinion, compromise the subject's safety Significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions. PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcB / QTcF interval &gt; 450 msec obtained at screening visit or prior to the first dose of study drug. Liver function tests greater than the upper limit of normal. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening. Urinalysis positive for protein or glucose. A positive screen for alcohol, drugs of abuse, or tobacco use. Inability to comply with food and beverage restrictions during study participation. Donation or blood collection or acute loss of blood prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Safety/Efficacy Study</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
</DOC>